Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer|Early-stage Breast Cancer
Interventions: DRUG: pyrotinib combined with Capecitabine|DRUG: treatment of physician's choice
Sponsor: Peking Union Medical College Hospital